N. M. Borradaile, L. E. de Dreu and M. W. Huff, “Inhibition of Net HepG2 Cell Apolipoprotein B Secretion by the Citrus Flavonoid Naringenin Involves Activation of Phosphatidylinositol 3-Kinase, Independent of Insulin Receptor Substrate-1 Phosphorylation,” Diabetes, Vol. 52, No. 10, 2003, pp. 2554-2561.
http://dx.doi.org/10.2337/diabetes.52.10.2554

has been cited by the following article:

• TITLE: An Updated Mini Review on Grapefruit: Interactions with Drugs, Obesity and Cardiovascular Risk Factors

  AUTHORS: Dimitrios Papandreou, Andry Phily

  KEYWORDS: Grapefruit; Drug Interactions; Obesity; Cardiovascular Risk Factors

  JOURNAL NAME: Food and Nutrition Sciences, Vol.5 No.4, February 11, 2014

  ABSTRACT: The paper examines the effects of grapefruit consumption in relation to drugs, obesity and cardiovascular risk factors. The review includes the most updated studies found in Pub-Med. The grapefruit effect refers to the ability of grapefruit juice and supplements to interact with a wide variety of pharmaceuticals, either enhancing or limiting their systemic availability. Due to altering the active dosage of the pharmaceutical, Grapefruit juice is commonly not allowed to be used alongside with many drugs. Naringin is the most important one, which can inhibit absorption of some drugs but more commonly 6’7’-dihydroxybergamottin, which inhibits CYP3A4. Lately, grapefruit has been found both in rats and adults to reduce body weight, blood pressure, improve lipid and hepatic profile and decrease platelet aggregation. These promising results must be followed by additional studies in order to add to the importance of the role and effects of grapefruit as part of our diet.